Immatics (NASDAQ:IMTXW) Sees Large Increase in Short Interest

Immatics (NASDAQ:IMTXW) was the target of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 78,300 shares, an increase of 48.3% from the February 13th total of 52,800 shares. Based on an average trading volume of 26,100 shares, the short-interest ratio is presently 3.0 days.

Immatics Stock Up 93.5 %

NASDAQ IMTXW traded up $0.02 during mid-day trading on Monday, reaching $0.04. 21,915 shares of the stock were exchanged, compared to its average volume of 23,839. The business’s fifty day simple moving average is $0.05 and its 200 day simple moving average is $0.82. Immatics has a 1-year low of $0.02 and a 1-year high of $4.00.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.